This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D.,
Bell, J.,
Mancuso, J. Y.,
Kupiec, J. W.,
Sabbagh, M. N.,
van Dyck, C.,
Thomas, R. G.,
Aisen, P. S.
Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]
Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment
Fujiwara, Yoshinori,
Suzuki, Hiroyuki,
Yasunaga, Masashi,
Sugiyama, Mika,
Ijuin, Mutsuo,
Sakuma, Naoko,
Inagaki, Hiroki,
Iwasa, Hajime,
Ura, Chiaki,
Yatomi, Naomi,
Ishii, Kenji,
Tokumaru, Aya M,
Homma, Akira,
Nasreddine, Ziad,
Shinkai, Shoji
Aim: The Montreal Cognitive Assessment (MoCA), developed by Dr Nasreddine (Nasreddine et al. 2005), is a brief cognitive screening tool for detecting older people with mild cognitive impairment (MCI). We examined the reliability and validity of the Japanese version of the MoCA (MoCA-J) in older Japanese subjects.; Methods: Subjects were recruited from the outpatient memory […]
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation
Freund, Hans-Joachim,
Kuhn, Jens,
Lenartz, Doris,
Mai, Jürgen K.,
Schnell, Thomas,
Klosterkoetter, Joachim,
Sturm, Volker
Background: Dementia represents one of the most challenging health problems. Despite intense research, available therapies have thus far only achieved modest results. Deep brain stimulation (DBS) is an effective treatment option for some movement disorders and is under study for psychiatric applications. Recently, diencephalic DBS revealed selective effects on memory functions, another facet of subcortical […]
Object alternation: a novel probe of medial frontal function in frontotemporal dementia
Freedman, Morris,
Binns, Malcolm A.,
Black, Sandra E.,
Levine, Brian,
Miller, Bruce L.,
Ramirez, Joel,
Szilagyi, Gregory M.,
Scott, Christopher J. M.,
McNeely, Alicia A.,
Stuss, Donald T.
We studied behavioral variant frontotemporal dementia (bvFTD) using object alternation (OA) as a novel probe of cognition. This task was adopted from animal models and is sensitive to ventrolateral-orbitofrontal and medial frontal function in humans. OA was administered to bvFTD patients, normal controls, and a dementia control group with Alzheimer disease (AD). Two other frontal […]
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Flynn Longmire, Crystal V.,
Drye, Lea T.,
Frangakis, Constantine E.,
Martin, Barbara K.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Faxén-Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Hjorth, Erik,
Palmblad, Jan,
Vedin, Inger,
Cederholm, Tommy,
Wahlund, Lars-Olof
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]